Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable ...

Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) ...

If approved, patients could self-administer a weekly dose at home as an alternative to hospital intravenous dosing.

The US drug regulator has approved the Armlupeg (pegfilgrastim-unne) 6mg / 0.6 ml injection for subcutaneous use in a ...

This is the first and only subcutaneous immune checkpoint inhibitor in Europe that a health care provider can administer in ...

Eisai seeks Japanese PMDA approval for subcutaneous formulation of Leqembi to treat early Alzheimer’s disease: Tokyo Monday, December 1, 2025, 14:00 Hrs [IST] Eisai Co., Ltd. an ...

Eisai has submitted a new drug application to Japan’s Pharmaceuticals and Medical Devices Agency for a subcutaneous ...

The subcutaneous formulation of toripalimab demonstrated noninferior pharmacokinetics compared to the intravenous version in ...

If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 ...

Lunsumio provides high rates of deep and long-lasting responses in third-line and later follicular lymphoma, a disease that ...

Does Weight Loss Medication Work? Key takeaways Weight loss medications work for many people. They can help those with ...